Product Information
PAXLOVID 300-100 MG DOSE PACK is a brand product labeled by Pfizer Inc., priced at $49.2371 per EA under NDC 00069504530. Its NADAC has been published 59 times since Aug 20, 2025.
FDA first approved this application on May 25, 2023.
Manufacturer
Pfizer Inc.NDC
00069504530
Classification
Brand
Dosage Form
KIT
Effective Date
9/23/2026
Approval Type
New Drug (NDA)
FDA Application
NDA217188FDA Approved
5/25/2023
On Market Since
7/9/2025
Price Statistics
The NADAC for PAXLOVID 300-100 MG DOSE PACK has been published 59 times since Aug 20, 2025, and over the history we have for it it has risen 2.9%. The table below summarizes its recorded NADAC range and movement.
| Current price | $49.2371 per EA |
|---|---|
| All-time high | $49.2992 (May 13, 2026) |
| All-time low | $47.8414 (Nov 19, 2025) |
| 52-week high | $49.2992 |
| 52-week low | $47.8414 |
| Median price | $49.2353 |
| Average price | $48.8094 |
| Largest weekly change | +3.0% (Dec 31, 2025) |
| Weeks tracked | 59 |
| Tracking since | Aug 20, 2025 |
Generic Alternatives
The matcher finds 1 manufacturer offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Pfizer Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
nirmatrelvir and ritonavir market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of PAXLOVID 300-100 MG DOSE PACK?
The current National Average Drug Acquisition Cost (NADAC) for PAXLOVID 300-100 MG DOSE PACK, manufactured by Pfizer Inc., is $49.2371 per EA (NDC 00069504530), effective Sep 30, 2026.
How has the price of PAXLOVID 300-100 MG DOSE PACK changed over time?
Over the history we have for it, the NADAC for PAXLOVID 300-100 MG DOSE PACK has risen 2.9%. It has been tracked across 59 weekly CMS publications since Aug 20, 2025.
What are the highest and lowest recorded NADAC prices for PAXLOVID 300-100 MG DOSE PACK?
Since Aug 20, 2025, the NADAC for PAXLOVID 300-100 MG DOSE PACK has ranged from a low of $47.8414 (Nov 19, 2025) to a high of $49.2992 (May 13, 2026), with a median of $49.2353 per EA.
Are there cheaper alternatives to PAXLOVID 300-100 MG DOSE PACK?
1 manufacturer publishes a NADAC-priced product with the same active ingredient and strength as PAXLOVID 300-100 MG DOSE PACK in a comparable dosage form, but none are currently priced below it.
Who manufactures PAXLOVID 300-100 MG DOSE PACK?
PAXLOVID 300-100 MG DOSE PACK (NDC 00069504530) is labeled by Pfizer Inc., and CMS classifies it as a brand product.